Accepted for Publication: February 22, 2012.
Published Online: May 7, 2012. doi:10.1001/archpediatrics.2012.209
Author Contributions:Study concept and design: Meier, Troost, and Anthony. Acquisition of data: Meier, Troost, and Anthony. Analysis and interpretation of data: Meier, Troost, and Anthony. Drafting of the manuscript: Meier, Troost, and Anthony. Critical revision of the manuscript for important intellectual content: Meier, Troost, and Anthony. Statistical analysis: Meier, Troost, and Anthony. Obtained funding: Anthony. Administrative, technical, and material support: Meier and Anthony. Study supervision: Anthony.
Financial Disclosure: In addition to the National Institute on Drug Abuse and Michigan State University funding/support listed herein, Dr Anthony has received payments in the form of honoraria, scientific advisory board compensation, and consultation fees for his service as a nonemployee consultant of the US Food and Drug Administration and of CRS Associates, Inc, on topics pertinent to postmarketing surveillance of prescription opioids, including products by Reckitt-Benckhiser and Purdue Pharma.
Funding/Support: This study was supported by grants R01DA016558, K05DA015799, and T32DA021129 from the National Institute on Drug Abuse and by Michigan State University.
Disclaimer: The content is the sole responsibility of the authors and does not necessarily represent the official views of Michigan State University, the National Institute on Drug Abuse, or the National Institutes of Health.
Additional Contributions: We thank the US Substance Abuse and Mental Health Services Administration Office of Applied Studies (now the Center for Behavioral Health Statistics and Quality) for completion of its annual nationally representative surveys on drug use and health, as well as its direction and supervision of the annual data gathering and preparation of public use data sets.